BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 22748304)

  • 1. Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis.
    Caponetti GC; Miranda RN; Althof PA; Dobesh RC; Sanger WG; Medeiros LJ; Greiner TC; Weisenburger DD
    Hum Pathol; 2012 Dec; 43(12):2223-8. PubMed ID: 22748304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c-kit-negative desmoid tumours?
    Liegl B; Leithner A; Bauernhofer T; Windhager R; Guelly C; Regauer S; Beham A
    Histopathology; 2006 Dec; 49(6):576-81. PubMed ID: 17163842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of histiocytoses to imatinib mesylate: fire to ashes.
    Janku F; Amin HM; Yang D; Garrido-Laguna I; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Nov; 28(31):e633-6. PubMed ID: 20733125
    [No Abstract]   [Full Text] [Related]  

  • 6. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
    Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
    Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
    Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis.
    Chen W; Wang J; Wang E; Lu Y; Lau SK; Weiss LM; Huang Q
    Am J Surg Pathol; 2010 Jul; 34(7):1049-57. PubMed ID: 20551822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors.
    Welin S; Fjällskog ML; Saras J; Eriksson B; Janson ET
    Neuroendocrinology; 2006; 84(1):42-8. PubMed ID: 17047316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
    Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors.
    Fjällskog ML; Lejonklou MH; Oberg KE; Eriksson BK; Janson ET
    Clin Cancer Res; 2003 Apr; 9(4):1469-73. PubMed ID: 12684421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders.
    Lau SK; Chu PG; Weiss LM
    Am J Surg Pathol; 2008 Apr; 32(4):615-9. PubMed ID: 18277880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
    Fiorentini G; Rossi S; Lanzanova G; Biancalani M; Palomba A; Bernardeschi P; Dentico P; De Giorgi U
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):17-20. PubMed ID: 16767900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow involvement of Langerhans cell histiocytosis: immunohistochemical evaluation of bone marrow for CD1a, Langerin, and S100 expression.
    Kim HK; Park CJ; Jang S; Cho YU; Park SH; Koh KN; Im HJ; Seo JJ
    Histopathology; 2014 Dec; 65(6):742-8. PubMed ID: 25138018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skin-limited Langerhans' cell histiocytosis in children.
    Hussein MR
    Cancer Invest; 2009 Jun; 27(5):504-11. PubMed ID: 19308811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
    Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
    Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.